

Fabio L Cury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7799949/publications.pdf>

Version: 2024-02-01

64
papers

930
citations

430874

18
h-index

501196

28
g-index

65
all docs

65
docs citations

65
times ranked

1434
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. <i>Practical Radiation Oncology</i> , 2022, 12, e34-e39.	2.1	3
2	Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 194.e15-194.e22.	1.6	3
3	Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. <i>European Urology Open Science</i> , 2022, 36, 26-33.	0.4	6
4	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.6	2
5	Meta-analysis of Elective Pelvic Nodal Irradiation Using Moderate Hypofractionation for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1044-1053.	0.8	5
6	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 174-185.	0.8	77
7	Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 299.e7-299.e14.	1.6	5
8	Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. <i>World Journal of Urology</i> , 2021, 39, 1331-1343.	2.2	34
9	Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 738-741.	0.8	27
10	Practical considerations for prostate hypofractionation in the developing world. <i>Nature Reviews Urology</i> , 2021, 18, 669-685.	3.8	20
11	Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 293-305.	0.9	3
12	Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. <i>Physica Medica</i> , 2020, 69, 36-43.	0.7	16
13	Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer. <i>Practical Radiation Oncology</i> , 2020, 10, e514-e520.	2.1	9
14	Psychological functioning, coping styles and their relationship to appraisal of physical limitations following invasive surgical procedures for soft-tissue sarcoma: A qualitative study. <i>Journal of Surgical Oncology</i> , 2020, 121, 1266-1275.	1.7	1
15	MP61-08: A PHASE I/II TRIAL OF TRANSURETHRAL SURGERY FOLLOWED BY A COMBINATION OF ATEZOLIZUMAB AN ANTI-PDL-1 (MPDL3280A) WITH TRIMODAL THERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2020, 203, e938.	0.4	3
16	Improving ultrasound-based prostate volume estimation. <i>BMC Urology</i> , 2019, 19, 68.	1.4	18
17	Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, 24-28.	2.1	7
18	Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e201-e210.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. <i>Cureus</i> , 2018, 10, e2238.	0.5	20
20	Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1340-1351.	4.9	30
21	Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, 264-269.	2.1	11
22	Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. <i>CMAJ Open</i> , 2017, 5, E265-E272.	2.4	12
23	PD24-05 IMPACT OF ABIRATERONE ACETATE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
24	Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 105-112.	0.4	9
25	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 94.	0.6	0
26	Supplementary data: External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 126.	0.6	0
27	Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 47-47.	1.6	0
28	Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis. <i>Cancer</i> , 2016, 122, 1085-1096.	4.1	21
29	MP46-18 USE OF ABIRATERONE ACETATE IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A REAL-LIFE COST EFFECTIVENESS STUDY. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
30	MP46-19 CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN QUEBEC: MEDICATION USE IN THE LAST YEAR OF LIFE. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
31	The Role of HMGB1 in Radioresistance of Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 471-479.	4.1	58
32	Abstract 1654: p21 WAF1/Cip1 -mediated radiosensitization of bladder cancer cells by mTOR inhibitor, RAD001 disrupts the balance between autophagy and apoptosis. , 2016, , .		0
33	Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. <i>Canadian Journal of Urology</i> , 2016, 23, 8209-14.	0.0	3
34	Brachytherapy Improves Biochemical Failure-Free Survival in Low- and Intermediate-Risk Prostate Cancer Compared With Conventionally Fractionated External Beam Radiation Therapy: A Propensity Score Matched Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 505-516.	0.8	57
35	Electrochemical red-ox therapy of prostate cancer in nude mice. <i>Bioelectrochemistry</i> , 2015, 104, 1-9.	4.6	18
36	Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 107-113.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. <i>Practical Radiation Oncology</i> , 2015, 5, 406-410.	2.1	5
38	Current era clinical outcomes of castration-resistant prostate cancer in real-life population study in Quebec, Canada.. <i>Journal of Clinical Oncology</i> , 2015, 33, 226-226.	1.6	0
39	Abstract 3316: The role of high mobility group box 1 in the combination therapy of gemcitabine and radiation in muscle invasive bladder cancer. , 2015, , .		0
40	Clinical Management and Burden of Prostate Cancer: A Markov Monte Carlo Model. <i>PLoS ONE</i> , 2014, 9, e113432.	2.5	10
41	Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. <i>CMAJ Open</i> , 2014, 2, E60-E68.	2.4	19
42	Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. <i>Brachytherapy</i> , 2014, 13, 450-455.	0.5	9
43	Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. <i>BMC Health Services Research</i> , 2014, 14, 252.	2.2	31
44	Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 326-331.	0.8	72
45	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 60-69.	4.9	12
46	Canadian cost comparison of different forms of androgen ablative therapies prior and during the castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16029-e16029.	1.6	0
47	Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. <i>Cancer</i> , 2013, 119, 1999-2004.	4.1	18
48	222 ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER COMPARED WITH IMMEDIATE TREATMENT: A UNITED STATES - CANADIAN ECONOMIC COMPARISON. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
49	Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 534-539.	0.8	27
50	Endoscopic Vascular Targeted Photodynamic Therapy with the Photosensitizer WST11 for Benign Prostatic Hyperplasia in the Preclinical Dog Model. <i>Journal of Urology</i> , 2013, 190, 1946-1953.	0.4	11
51	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. <i>Radiotherapy and Oncology</i> , 2013, 109, 204-210.	0.6	34
52	Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment. <i>PLoS ONE</i> , 2013, 8, e65257.	2.5	26
53	Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes.. <i>Journal of Clinical Oncology</i> , 2013, 31, 141-141.	1.6	0
54	Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer – Long Term Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1417-1423.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Refining the orthotopic dog prostate cancer (DPC) model to better bridge the gap between rodents and men. <i>Prostate</i> , 2012, 72, 752-761.	2.3	17
56	Abstract 1452: mTOR inhibition radiosensitizes bladder cancer tumor cells in vitro and in vivo: A novel strategy for treatment. , 2012, , .		0
57	Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 309-313.	1.6	9
58	Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. <i>Radiotherapy and Oncology</i> , 2011, 101, 486-489.	0.6	14
59	Radiation therapy and androgen deprivation in the management of high risk prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011, 37, 161-179.	1.5	15
60	Dosimetric consequences of misalignment and realignment in prostate 3DCRT using intramodality ultrasound image guidance. <i>Medical Physics</i> , 2010, 37, 2787-2795.	3.0	17
61	Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy. <i>Brachytherapy</i> , 2010, 9, 208-212.	0.5	13
62	Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 805-810.	0.8	38
63	Organ-sparing strategies in the management of invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1765-1775.	2.4	8
64	Evaluation of a prototype 3D ultrasound system for multimodality imaging of cervical nodes for adaptive radiation therapy. , 2007, , .		3